Covered recipient · General Payments record
MIA M STOKES
Physician Assistants & Advanced Practice Nursing Providers Physician Assistant
General Payments · PY2021–2024
$2,756.97
- Reported across 81 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $514.67 | 17 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| OptiNose US, Inc. | $239.54 | 10 |
| GENZYME CORPORATION | $157.82 | 4 |
| Medtronic, Inc. | $46.89 | 1 |
| REVANCE THERAPEUTICS, INC. | $46.38 | 1 |
| GlaxoSmithKline, LLC. | $24.04 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (17)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| GENZYME CORPORATION | $18.55 | 01/25/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1139994359 | CMS |
| GENZYME CORPORATION | $94.54 | 01/26/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1139994391 | CMS |
| GENZYME CORPORATION | $19.59 | 06/11/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1139994379 | CMS |
| GENZYME CORPORATION | $25.14 | 07/17/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1139994389 | CMS |
| GlaxoSmithKline, LLC. | $24.04 | 03/21/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1116644842 | CMS |
| Medtronic, Inc. | $46.89 | 12/11/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1116951955 | CMS |
| Optinose US, Inc. | $17.74 | 01/04/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1142178640 | CMS |
| Optinose US, Inc. | $20.84 | 01/30/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1142178648 | CMS |
| Optinose US, Inc. | $17.26 | 03/22/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1142178678 | CMS |
| Optinose US, Inc. | $3.71 | 04/12/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1142178908 | CMS |
| Optinose US, Inc. | $13.13 | 04/24/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1142178718 | CMS |
| Optinose US, Inc. | $9.88 | 05/07/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1142178700 | CMS |
| Optinose US, Inc. | $5.41 | 05/08/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1142178890 | CMS |
| Optinose US, Inc. | $19.74 | 05/21/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1142178900 | CMS |
| Optinose US, Inc. | $125.89 | 05/22/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1142178960 | CMS |
| Optinose US, Inc. | $5.94 | 06/03/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1142178894 | CMS |
| REVANCE THERAPEUTICS, INC. | $46.38 | 05/09/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1147951698 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2021, 2022, 2023, 2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.